This article is for informational and educational purposes only and does not constitute medical advice. Ipamorelin is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Novo Nordisk A/S. This research review is compiled from publicly available peer-reviewed literature for educational purposes only.
Ipamorelin (development code NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue (GHS) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of approximately 711 Da. Originally developed at Novo Nordisk, it acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), stimulating pulsatile GH release from the anterior pituitary. Its principal pharmacological distinction from earlier GH-releasing peptides (GHRPs) — notably GHRP-2 and GHRP-6 — is its high selectivity for GH release relative to cortisol, prolactin, and ACTH, a profile first characterized by Raun et al. (1998). Preclinical studies have reported effects on longitudinal bone growth, body composition, and IGF-1 elevation in rodent models. Early-phase clinical investigations were conducted in several indications; however, no regulatory approval has been granted for ipamorelin in any jurisdiction as of the review date. Ipamorelin is among the better-characterized growth hormone secretagogues in the published peptide pharmacology literature, though human efficacy and safety data remain limited.
1. Background
1.1 Growth Hormone Secretagogues and the GHSR Pathway
Growth hormone secretagogues are a class of compounds that stimulate GH release from the anterior pituitary through a receptor pathway distinct from the endogenous GHRH pathway used by tesamorelin and CJC-1295. The GHS receptor (GHSR-1a) was identified as the cognate receptor for this class in 1996, and its endogenous ligand was subsequently identified as ghrelin — a 28-amino-acid peptide primarily secreted from the stomach that regulates appetite, GH release, and energy homeostasis [4]. Synthetic GHSPs predate ghrelin’s discovery; the earliest GHRPs were developed in the 1970s and 1980s by Bowers and colleagues as analogues of enkephalin with unexpected GH-releasing activity.
GHSR-1a agonism and GHRH receptor agonism produce GH release through mechanistically complementary pathways that converge on the somatotroph cell and act synergistically: GHRH drives cAMP-mediated GH synthesis and release, while GHS receptor agonists primarily act through phospholipase C and intracellular calcium mobilization. When both pathways are activated simultaneously, GH release is substantially amplified beyond what either stimulus produces alone — a synergy that has been explored in combination research using ipamorelin alongside GHRH analogues.
1.2 Development of Ipamorelin — Selectivity as the Design Goal
First-generation GHRPs including GHRP-6 and GHRP-2 stimulated GH release effectively but also produced off-target hormonal effects: elevated cortisol, prolactin, and ACTH. These effects were not mechanistically desirable for most research applications and raised tolerability concerns for potential clinical use. Ipamorelin was designed by Novo Nordisk researchers to retain potent GHSR-1a agonism while eliminating these off-target endocrine effects. The compound was identified through a screen of synthetic peptide analogues and characterized in the foundational 1998 paper by Raun and colleagues, which established its selectivity profile and gave it the designation “the first selective growth hormone secretagogue” in the published literature [1].
2. Molecular Structure
Ipamorelin is a pentapeptide containing three non-standard residues that are critical to its receptor binding, selectivity, and metabolic stability.
| Property | Detail |
|---|---|
| Full sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Development code | NNC 26-0161 (Novo Nordisk) |
| Molecular weight | ~711 Da |
| Peptide length | 5 residues (pentapeptide) |
| Non-standard residues | Aib (position 1), D-2-Nal (position 3), D-Phe (position 4) |
| Aib at position 1 | α-aminoisobutyric acid (α-methyl alanine); resists aminopeptidase cleavage |
| D-2-Nal at position 3 | D-2-naphthylalanine; bulky aromatic; GHSR binding affinity determinant |
| D-Phe at position 4 | D-phenylalanine; D-configuration resists proteolytic degradation |
| C-terminus | Amide (–NH₂); protects against carboxypeptidase cleavage |
| Primary target | GHSR-1a (growth hormone secretagogue receptor 1a) |
The three non-standard structural elements of ipamorelin each contribute to its pharmacological profile. Aib (α-aminoisobutyric acid) at position 1 introduces a methyl group on the alpha carbon that prevents N-terminal aminopeptidase cleavage, extending plasma half-life relative to analogues with a standard L-amino acid at this position. D-2-Naphthylalanine at position 3 provides a large aromatic surface for hydrophobic interactions with the GHSR-1a binding pocket and is critical for high receptor affinity. D-Phenylalanine at position 4 confers resistance to chymotryptic and related proteases. The C-terminal lysine amide eliminates carboxypeptidase recognition. Together these modifications produce a peptide that is substantially more metabolically stable than native GHRP sequences while retaining potent receptor agonism.
3. Mechanism of Action
4. Key Research Findings
4.1 Foundational Characterization — Selectivity Profile
The foundational characterization of ipamorelin was published by Raun et al. (1998) in European Journal of Endocrinology [1]. The study compared ipamorelin with GHRP-6 and GHRP-2 in rat and swine models, measuring GH, cortisol, prolactin, and ACTH responses to equimolar doses. Ipamorelin produced GH release comparable to GHRP-6 but with substantially attenuated cortisol and prolactin responses at the same dose range. The paper introduced the characterization of ipamorelin as “the first selective growth hormone secretagogue” and established the hormonal selectivity as its principal pharmacological distinction. This 1998 characterization remains the most frequently cited primary source for ipamorelin’s pharmacological profile.
Schematic representation of relative hormonal responses from Raun et al. (1998) [1] comparing ipamorelin and GHRP-6 in preclinical models. Both compounds produced comparable GH release; ipamorelin showed markedly attenuated cortisol and prolactin responses. Values are qualitative representations of reported directional differences, not exact quantitative reproductions.
4.2 Bone Growth and Body Composition (Preclinical)
Johansen et al. (1999) evaluated the effects of ipamorelin on longitudinal bone growth in young rats, reporting that chronic subcutaneous ipamorelin administration increased tibial growth plate width and longitudinal bone growth rates compared with vehicle-treated controls [2]. IGF-1 levels were elevated in treated animals, consistent with GH-mediated hepatic IGF-1 synthesis. The study also reported body weight and lean mass increases in treated animals relative to controls. These findings contributed to interest in ipamorelin as a tool compound for studying GH-axis effects on skeletal and body composition parameters in in vivo models.
The anabolic and bone growth effects observed in juvenile rodent models reflect the expected downstream consequences of GH and IGF-1 elevation in a growing animal. Whether equivalent effects would be observed in mature or aged animals, and at what doses and dosing schedules, has not been systematically characterized across independently published studies.
4.3 GH Pulsatility and Pharmacokinetics
A key pharmacological feature of ipamorelin’s GH secretagogue profile is that the GH release it stimulates retains a pulsatile pattern, because the pituitary’s somatostatin-mediated feedback remains functional. Administered as a discrete subcutaneous injection, ipamorelin produces an acute GH pulse that typically resolves within 2–3 hours, returning GH concentrations toward baseline as somatostatin tone is re-established. This pulse-and-return pattern is mechanistically distinct from the continuous GH elevation seen with exogenous GH replacement and is proposed to produce a more physiological IGF-1 profile, though direct comparative human data on this distinction are not available in published controlled studies.
Plasma half-life of ipamorelin following subcutaneous administration has been estimated at approximately 2 hours in preclinical models based on GH pulse kinetics and peptide concentration decay. Published human pharmacokinetic data from controlled single-dose or multi-dose studies are not widely available in the peer-reviewed literature.
4.4 Early-Phase Clinical Investigations
Ipamorelin entered early-phase clinical investigation for several indications following its preclinical characterization. Published information on clinical trial results is limited. Smith (2005) reviewed the broader GHS class in the context of clinical development, noting ipamorelin among the compounds with clinical investigation underway at the time [3]. No Phase 3 trial for any indication has been published in peer-reviewed form, and no regulatory submission for ipamorelin has resulted in an approved product in any jurisdiction as of the review date.
5. Evidence Status
| Proposed Effect / Claim | Current Status | Evidence Level |
|---|---|---|
| GHSR-1a binding and GH release (mechanism) | Established in preclinical models; Raun et al. 1998 and follow-on studies | Moderate |
| Selectivity for GH vs. cortisol / prolactin | Preclinically established vs. GHRP-6/GHRP-2; Raun et al. 1998 | Moderate |
| Bone growth and longitudinal growth (preclinical) | Rodent studies; Johansen et al. 1999; not independently replicated at scale | Limited |
| Body composition / lean mass (preclinical) | Animal model data; secondary endpoints in preclinical work | Limited |
| Human GH secretagogue effect | Early-phase clinical data consistent with mechanism; not published at Phase 3 level | Limited |
| Synergy with GHRH analogues (human) | Mechanistically plausible; not established in published controlled human trials | Limited |
| Clinical efficacy (any approved indication) | No regulatory approval in any jurisdiction identified as of the review date | Limited |
What We Still Don’t Know
- Human pharmacokinetics and bioavailability: Detailed published pharmacokinetic data for ipamorelin in humans — including absorption rate, volume of distribution, metabolic clearance pathways, and active metabolite profile — are not available in peer-reviewed literature accessible for review. The metabolic fate of the non-standard residues (Aib, D-2-Nal, D-Phe) in human plasma and tissues has not been independently characterized in published studies.
- Whether GH selectivity observed preclinically translates to humans: The cortisol and prolactin-sparing selectivity that defines ipamorelin in rodent and swine models has not been fully replicated in published controlled human pharmacodynamic studies. Whether the selectivity advantage holds at human-relevant doses, dosing frequencies, and with chronic administration has not been established from available published data.
- Long-term effects of chronic GH pulse amplification: Neither the benefits nor the risks of repeated, chronic ipamorelin-mediated GH pulse stimulation over months to years have been established in published human studies. The long-term oncologic implications of sustained IGF-1 elevation via any GHS are not characterized at the level of hard endpoint data.
- Dose-response relationship in humans: Published dose-ranging studies in human subjects are not available in the peer-reviewed literature to establish the dose of ipamorelin required to produce a defined GH response, the dose at which off-target effects emerge, or the relationship between dose and IGF-1 elevation over time.
- Combination protocols with GHRH analogues: The mechanistic rationale for combining ipamorelin with GHRH analogues is sound, but the specific combination protocols proposed in research contexts (dose, timing, frequency) have not been evaluated in published randomized human studies for any specific outcome measure.
6. Limitations of Current Research
References
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552
- Johansen PB, Segev Y, Bex M, Bhattacharya K, Patchett AA, Smith RG, Thorner MO. “Ipamorelin, a new growth hormone releasing peptide, induces longitudinal bone growth in rats.” Growth Hormone & IGF Research. 1999;9(2):106–113. doi:10.1054/ghir.1999.9946
- Smith RG. “Development of growth hormone secretagogues.” Endocrine Reviews. 2005;26(3):346–360. doi:10.1210/er.2004-0019
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature. 1999;402(6762):656–660. doi:10.1038/45230
- Bowers CY, Momany FA, Reynolds GA, Hong A. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984;114(5):1537–1545. doi:10.1210/endo-114-5-1537